No data available
The world’s first global cloud-based, full-service branding, marketing and digital agency, UP has long supported Cambridge companies but opening our office here physically puts us closer to the innovation and the people driving it. That access means we can deliver even more impact for life science leaders looking to scale globally.
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.. . The ValiRx management team comprises a mix of entrepreneurial scientists who are founders of a number of medical life sciences companies and industry-specific personnel, all with extensive experience in transferring technologies and products into the commercial arena to generate revenue and growth of shareholder value.
Watch our Member Showcase Video https://bit.ly/3fB4WZq
Watch our Member Showcase Video https://bit.ly/3fB4WZq
No data available
VasoDynamics is a Stevenage and London based, clinical-stage pharmaceutical development company. We are solely focused on developing patient-friendly, cost-effective medicines to prevent the severe side-effects induced by anticancer therapies. Our programmes are designed to prevent the common complications of cancer therapy, including mouth ulceration, dermatitis, and (permanent) hair-loss. Our philosophy is to generate affordable medicines that enable cancer patients to tolerate widely used anticancer therapies, with the dual purpose of enhancing the efficacy of anti-cancer therapy and improving patients’ quality of life with cancer, without painful, traumatic or debilitating side-effects.
No data available
Velora Evidence is an evidence-generation and medical affairs consultancy specialising in real-world evidence. We work with organisations developing medicines and health technologies, helping them plan, generate and communicate evidence across the full product lifecycle. Our expertise spans evidence strategy and real-world study design through to patient-centred research, scientific communications and continuing evidence oversight.
Veranova is a global leader in the development and manufacturing of specialist and complex APIs for pharma and biotech customers. We have over 50 years of experience navigating the challenges of the global healthcare industry, and nurturing long-standing, trusted customer relationships.
Under our Pharmorphix® brand, we have a proven track record of delivering excellence for customers in early drug development. By applying our world-leading understanding of solid form science, we can improve the properties and success rates of drug candidates for the pharmaceutical industry. Visit https://www.veranova.com to discover more.
Watch Our Youtube Video: https://www.youtube.com/watch?v=ql3hyeQm-gE
/>
Under our Pharmorphix® brand, we have a proven track record of delivering excellence for customers in early drug development. By applying our world-leading understanding of solid form science, we can improve the properties and success rates of drug candidates for the pharmaceutical industry. Visit https://www.veranova.com to discover more.
Watch Our Youtube Video: https://www.youtube.com/watch?v=ql3hyeQm-gE
/>
Vernalis Research develop and apply fragment and structure-based methods to solve problems in drug discovery, and have generated cell active lead compounds and development candidates against targets in oncology, neurodegeneration, anti-infectives and inflammation.
The Company balances an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Its shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and they seek additional partnerships.
Vernalis Research also have an extensive portfolio of partnered and unpartnered drug candidates in pre-clinical and clinical development.
The Company balances an internal portfolio of drug discovery projects with fully integrated research collaborations on targets with pharmaceutical companies and academic partners. Its shared-risk approach ensures a high level of engagement from our scientists and rewards success. Current disclosed collaborations include those with Servier, Daiichi Sankyo, Lundbeck and Asahi Kasei Pharma, and they seek additional partnerships.
Vernalis Research also have an extensive portfolio of partnered and unpartnered drug candidates in pre-clinical and clinical development.
Somaserve is a UCL spin out, a uniquely positioned specialist reagent and pharma service business which exploits the proprietary polyNaut™ technology (a ‘bionic’ nanoparticle vesicle). The reagent products are highly differentiated and address an unfulfilled area in the live cell imaging market. The ‘fee for service’ offering solves molecule viability problems for clients presenting a new approach to drug discovery.